HUMABFC
Live / Registered — Cancelled — Section 71 (as of 24 Jan 2025)
What this means for you
Registered since 10 Jul 2018. The owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 79207192
- Registration number
- 5510331
- Mark type
- Stylized text
- Filed
- 14 Dec 2016
- Published for opposition
- 24 Apr 2018
- Registered
- 10 Jul 2018
- Attorney of record
- Monte L. Falcoff/Jessica S. Sachs
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical products and preparations for the treatment of cancer, autoimmune disorders, inflammatory disorders, viral and bacterial infections, blood diseases; medicines for cancer, autoimmune disorders, inflammatory disorders, viral and bacterial infections, blood diseases; protein supplements; diagnostic kits consisting primarily of monoclonal antibodies and fragment crystallizable proteins, buffers, and reagents for use in disease testing
- Class 042 — Scientific and technological services: Scientific and technological services, namely, scientific research and analysis in the field of monoclonal antibodies and fragment crystallizable proteins; design and development of medical products, namely, pharmaceutical compositions of monoclonal antibodies and fragment crystallizable proteins; scientific study and research in the field of the prevention and the treatment of cancer, autoimmune disorders, inflammatory disorders, viral and bacterial infections, blood diseases; research and development in the field of the prevention and the treatment of cancer, autoimmune disorders, inflammatory disorders, viral and bacterial infections, blood diseases; cellular and molecular biological research; testing, inspection or research of pharmaceuticals; medical and scientific research, namely, conducting clinical trials for others; consulting in the field of medical research; engineering; genetic engineering; scientific research services using protein expression platform technology for research and development of pharmaceuticals; scientific research services using protein expression platform technology for manufacturing protein-based therapeutics; medical and scientific research of recombinant protein platform technologies designed to lead to new human vaccines, therapeutic proteins and antibodies; scientific laboratory services in the field of monoclonal antibodies
Owner
Prosecution history
- 24 Sept 2025 — TOTAL INVALIDATION OF REG EXT PROTECTION CREATED
- 24 Jan 2025 — CANCELLED SECTION 71
- 04 May 2024 — NEW REPRESENTATIVE AT IB RECEIVED
- 10 Jul 2023 — COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
- 09 Apr 2021 — NEW REPRESENTATIVE AT IB RECEIVED
- 06 Apr 2021 — CORRECTION FROM THE IB EXAMINED, NO ACTION IS NEEDED
- 03 Apr 2021 — CORRECTION TRANSACTION RECEIVED FROM IB
- 05 Mar 2021 — NEW REPRESENTATIVE AT IB RECEIVED
- 21 Dec 2018 — FINAL DECISION TRANSACTION PROCESSED BY IB
- 16 Oct 2018 — GENERIC MADRID TRANSACTION SENT TO IB
- 16 Oct 2018 — GENERIC MADRID TRANSACTION CREATED
- 10 Oct 2018 — FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
- 10 Jul 2018 — REGISTERED-PRINCIPAL REGISTER
- 24 Apr 2018 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 24 Apr 2018 — PUBLISHED FOR OPPOSITION